CRIS Current Research Information System

PALLADINI, ARIANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.289
AS - Asia 2.574
EU - Europa 2.228
AF - Africa 189
SA - Sud America 120
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.406
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.240
CN - Cina 806
SG - Singapore 663
VN - Vietnam 659
IT - Italia 594
GB - Regno Unito 447
DE - Germania 276
SE - Svezia 200
HK - Hong Kong 192
RU - Federazione Russa 115
IN - India 101
BR - Brasile 88
NL - Olanda 86
UA - Ucraina 86
FR - Francia 80
IE - Irlanda 76
CH - Svizzera 75
CI - Costa d'Avorio 71
TG - Togo 45
ZA - Sudafrica 43
KR - Corea 42
CA - Canada 38
JP - Giappone 38
FI - Finlandia 37
EE - Estonia 35
BG - Bulgaria 32
BE - Belgio 23
ID - Indonesia 19
AR - Argentina 14
JO - Giordania 13
LT - Lituania 13
RO - Romania 13
AT - Austria 11
SC - Seychelles 10
MX - Messico 9
PL - Polonia 9
EC - Ecuador 7
EG - Egitto 7
NG - Nigeria 6
BD - Bangladesh 5
CO - Colombia 5
DK - Danimarca 5
IQ - Iraq 5
MA - Marocco 5
AU - Australia 4
HR - Croazia 4
TR - Turchia 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
ES - Italia 3
IR - Iran 3
PK - Pakistan 3
SA - Arabia Saudita 3
BY - Bielorussia 2
GR - Grecia 2
KG - Kirghizistan 2
LB - Libano 2
LI - Liechtenstein 2
TW - Taiwan 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
DO - Repubblica Dominicana 1
IL - Israele 1
JM - Giamaica 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
MN - Mongolia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PS - Palestinian Territory 1
SN - Senegal 1
TH - Thailandia 1
UZ - Uzbekistan 1
ZM - Zambia 1
Totale 8.406
Salva come PNG Salva come JPEG
Città #
Singapore 455
Fairfield 392
Ashburn 388
Southend 370
Chandler 328
Hong Kong 192
Shanghai 174
Houston 172
Woodbridge 172
Wilmington 170
Ann Arbor 158
Seattle 144
Bologna 142
Dong Ket 132
Cambridge 130
Ho Chi Minh City 129
Hanoi 111
Santa Clara 110
Hefei 102
Beijing 99
Princeton 93
Dublin 76
Abidjan 71
Bern 70
Boardman 65
Jacksonville 49
Lomé 45
Milan 40
Los Angeles 39
Seoul 39
Westminster 39
Bremen 36
Nanjing 36
Dallas 35
Padova 33
Tokyo 33
Berlin 32
Sofia 32
Guangzhou 27
Helsinki 26
Jinan 26
Redmond 26
Redwood City 24
Brussels 23
Buffalo 22
Redondo Beach 21
Saint Petersburg 21
Casalecchio di Reno 20
New York 20
Falkenstein 19
Frankfurt am Main 18
Ottawa 18
Tianjin 18
Changsha 17
Jakarta 17
San Diego 17
Turin 17
London 16
Shenyang 15
Hebei 14
Toronto 14
Amman 13
Amsterdam 13
Des Moines 13
Hải Dương 13
Jiaxing 12
Nanchang 12
Phoenix 12
São Paulo 12
Da Nang 11
Haiphong 11
Bengaluru 10
Biên Hòa 10
Ha Long 10
Mülheim 10
Zhengzhou 10
Moscow 9
Vienna 9
Lappeenranta 8
Quận Bình Thạnh 8
Vicenza 8
Bühl 7
Chieti 7
Crocetta 7
Kerpen 7
Ningbo 7
Warsaw 7
Chicago 6
Council Bluffs 6
Crotone 6
Dearborn 6
Delhi 6
Mahé 6
Poplar 6
Porto Recanati 6
Quận Một 6
Shijiazhuang 6
Abeokuta 5
Bắc Giang 5
Haikou 5
Totale 5.720
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 380
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 353
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 305
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 278
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 242
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 221
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 213
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases 198
Virus-like particle display of HER2 induces potent anti-cancer responses 193
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 186
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 186
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 183
ImmunoGrid: Towards agent-based simulations of the human immune system at a natural scale 178
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 176
Cancer immunoprevention: from mice to early clinical trials 175
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 175
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 173
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 169
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 169
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 167
Antimetastatic activity of a preventive cancer vaccine. 166
In silico modeling and in vivo efficacy of cancer preventive vaccinations 165
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 163
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 162
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 162
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 161
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 157
Modeling the competition between lung metastases and the immune system using agents. 156
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 154
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 153
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. 152
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 152
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 150
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 149
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 149
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 148
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 144
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 141
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 141
Translational immunomics of cancer prevention. 141
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 140
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 138
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 125
Computational models as novel tools for cancer vaccines. 124
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer 119
Mathematical and computational models in tumor immunology 117
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 109
ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design, and optimization 106
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma 101
Predictive models in tumor immunology. 83
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 40
Development of cellular models expressing cynomolgus (Macaca fascicularis) HER2 for the functional evaluation of cross-reactive anti-human HER2 response 21
Totale 8.609
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.342
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.342
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021674 0 0 0 0 0 40 63 131 90 44 43 263
2021/20221.005 102 47 83 38 99 70 29 54 52 66 223 142
2022/20231.261 132 154 67 183 75 99 44 66 180 54 103 104
2023/2024490 25 45 22 32 29 50 25 209 7 19 11 16
2024/20251.409 102 166 112 75 230 78 101 68 9 115 82 271
2025/20261.734 484 323 242 230 315 140 0 0 0 0 0 0
Totale 8.609